Table 1.
Clinical presentations by different immunohistochemical scores in HER2-negativebreast cancer.
| HER2-0 (n = 246) |
HER2-Low (n = 369) |
p Value * | |
|---|---|---|---|
| Age (years) | 0.742 | ||
| <55 | 120 (48.7%) | 175 (47.4%) | |
| ≥55 | 126 (51.2%) | 194 (52.5%) | |
| Tumor size | 0.878 | ||
| T1 (≤2cm) | 87 (35.3%) | 146 (39.5%) | |
| T2 (2.1–5 cm) | 126(51.2%) | 166 (44.9%) | |
| T3 (>5 cm) | 20 (8.1%) | 24(6.5%) | |
| T4 | 12 (4.8%) | 33(8.9%) | |
| NA | 1 (0.4%) | 0 (0%) | |
| Node | 0.182 | ||
| N0 | 131 (53.2%) | 196 (53.1%) | |
| N1 | 74 (30.1%) | 90 (24.4%) | |
| N2 | 25 (10.2%) | 42 (11.4%) | |
| N3 | 14 (5.7%) | 39 (10.6%) | |
| NA | 2 (0.8%) | 2 (0.5%) | |
| Stage | 0.020 * | ||
| I | 68 (27.7%) | 116 (31.4%) | |
| II | 121 (49.2%) | 137 (37.1%) | |
| III | 35 (14.2%) | 77 (20.9%) | |
| IV | 22 (8.9%) | 39 (10.6%) |
HER2-0, HER2 immunohistochemistry score = 0; HER2-low was defined as HER2 immunohistochemistry score (+/++ with FISH (-); * p value via Chi-Square or Fisher’s exact test.